Isis Pharmaceuticals (ISIS) 40.87 $ISIS
Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.
Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.84%
Comtex SmarTrend(R) - Thu Sep 11, 4:34PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $38.84 to a high of $41.07. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $39.90 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
'Mad Money' Lightning Round: Buy, Buy, Buy Flextronics
at The Street - Thu Sep 11, 5:00AM CDT
Cramer likes Xerox, Sysco and Seattle Genetics.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
Isis Pharmaceuticals Shares Up 15.6% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Wed Sep 10, 11:14AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 1 month, Isis Pharmaceuticals has returned 15.59% as of today's recent price of $38.29.
National Association of Professional Women Announces Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, a 2014 Professional Woman of the Year
PRWeb - Mon Sep 08, 11:06PM CDT
NAPW honors Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, as a 2014 Professional Woman of the Year. Ms. Phillips-Smith is recognized with this prestigious distinction for leadership in clinical science. As the largest networking organization of professional women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a vibrant networking community with over 600,000 members and nearly 300 Local Chapters.
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Isis Pharmaceuticals Falls 2.12% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 05, 4:48PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $37.06 to a high of $38.98. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $38.95 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Isis Pharmaceuticals Has Returned 24.7% Since SmarTrend Recommendation (ISIS)
Comtex SmarTrend(R) - Wed Sep 03, 9:46AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 4 weeks, Isis Pharmaceuticals has returned 24.68% as of today's recent price of $41.30.
Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 03, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY.
ATL1103 Phase II Trial - Successful Efficacy Results
PR Newswire - Tue Sep 02, 6:19PM CDT
Antisense Therapeutics Limited ("ANP" or "the Company"
is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The Phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I (sIGF-I) levels of 26% from baseline (P<0.0001) at week 14 (one week past the last dose) at the 400mg per week dose tested.
Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
PR Newswire - Tue Sep 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from three drugs in its lipid franchise were highlighted in four presentations at the 2014 European Society of Cardiology (ESC) Congress in Barcelona Spain. Isis has created a lipid franchise of antisense drugs designed to provide effective and safe therapeutic options to treat patients with lipid disorders. This franchise is composed of one commercialized drug and several other drugs in clinical development designed to treat cardiovascular conditions by reducing specific lipid parameters that are risk factors for cardiovascular disease. Data presented include:
Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 3:55PM CDT
Isis Pharmaceuticals, Inc. (ISIS) has initiated a phase III study which will evaluate the use of ISIS-APOCIIIRx.
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
3 Health Care Stocks Pushing The Sector Higher
at The Street - Thu Aug 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Isis Pharmaceuticals reports launch of Phase 3 study of ISIS-APOCIII Rx in patients with the rare orphan disease characterised by extremely high triglyceride levels FCS
M2 - Thu Aug 28, 7:16AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) announced on Thursday that it has initiated a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS), a rare orphan disease that is characterised by extremely high triglyceride levels.
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
PR Newswire - Thu Aug 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. The Phase 3 study of ISIS-APOCIIIRx is a randomized, double-blind, placebo-controlled, six month study in approximately 50 patients diagnosed with FCS. The study will evaluate the efficacy and safety of a 300 mg once weekly dose of ISIS-APOCIIIRx. The primary endpoint of the study is percent change in fasting triglycerides from baseline after three months of dosing.
Global Cytomegalovirus Retinitis Market Report 2014 - Forecasts to 2018
M2 - Thu Aug 28, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rhbrc/global) has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. The Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis. An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug. According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis. Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Hospira - Shire Other Prominent Vendors - Auritec Pharmaceuticals - Chimerix Pharmaceuticals - Isis Pharmaceuticals - pSivida - Sanofi For more information visit http://www.researchandmarkets.com/research/5rhbrc/global
Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.
Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.84%
Comtex SmarTrend(R) - Thu Sep 11, 4:34PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $38.84 to a high of $41.07. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $39.90 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
'Mad Money' Lightning Round: Buy, Buy, Buy Flextronics
at The Street - Thu Sep 11, 5:00AM CDT
Cramer likes Xerox, Sysco and Seattle Genetics.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
Isis Pharmaceuticals Shares Up 15.6% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Wed Sep 10, 11:14AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 1 month, Isis Pharmaceuticals has returned 15.59% as of today's recent price of $38.29.
National Association of Professional Women Announces Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, a 2014 Professional Woman of the Year
PRWeb - Mon Sep 08, 11:06PM CDT
NAPW honors Lou Ellen Phillips-Smith, Ph.D., Medical Writing Consultant, as a 2014 Professional Woman of the Year. Ms. Phillips-Smith is recognized with this prestigious distinction for leadership in clinical science. As the largest networking organization of professional women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a vibrant networking community with over 600,000 members and nearly 300 Local Chapters.
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Isis Pharmaceuticals Falls 2.12% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 05, 4:48PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $37.06 to a high of $38.98. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $38.95 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Isis Pharmaceuticals Has Returned 24.7% Since SmarTrend Recommendation (ISIS)
Comtex SmarTrend(R) - Wed Sep 03, 9:46AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 4 weeks, Isis Pharmaceuticals has returned 24.68% as of today's recent price of $41.30.
Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 03, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY.
ATL1103 Phase II Trial - Successful Efficacy Results
PR Newswire - Tue Sep 02, 6:19PM CDT
Antisense Therapeutics Limited ("ANP" or "the Company"
is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The Phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I (sIGF-I) levels of 26% from baseline (P<0.0001) at week 14 (one week past the last dose) at the 400mg per week dose tested. Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
PR Newswire - Tue Sep 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from three drugs in its lipid franchise were highlighted in four presentations at the 2014 European Society of Cardiology (ESC) Congress in Barcelona Spain. Isis has created a lipid franchise of antisense drugs designed to provide effective and safe therapeutic options to treat patients with lipid disorders. This franchise is composed of one commercialized drug and several other drugs in clinical development designed to treat cardiovascular conditions by reducing specific lipid parameters that are risk factors for cardiovascular disease. Data presented include:
Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 3:55PM CDT
Isis Pharmaceuticals, Inc. (ISIS) has initiated a phase III study which will evaluate the use of ISIS-APOCIIIRx.
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery 3 Health Care Stocks Pushing The Sector Higher
at The Street - Thu Aug 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Isis Pharmaceuticals reports launch of Phase 3 study of ISIS-APOCIII Rx in patients with the rare orphan disease characterised by extremely high triglyceride levels FCS
M2 - Thu Aug 28, 7:16AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) announced on Thursday that it has initiated a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS), a rare orphan disease that is characterised by extremely high triglyceride levels.
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
PR Newswire - Thu Aug 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. The Phase 3 study of ISIS-APOCIIIRx is a randomized, double-blind, placebo-controlled, six month study in approximately 50 patients diagnosed with FCS. The study will evaluate the efficacy and safety of a 300 mg once weekly dose of ISIS-APOCIIIRx. The primary endpoint of the study is percent change in fasting triglycerides from baseline after three months of dosing.
Global Cytomegalovirus Retinitis Market Report 2014 - Forecasts to 2018
M2 - Thu Aug 28, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rhbrc/global) has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. The Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis. An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug. According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis. Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Hospira - Shire Other Prominent Vendors - Auritec Pharmaceuticals - Chimerix Pharmaceuticals - Isis Pharmaceuticals - pSivida - Sanofi For more information visit http://www.researchandmarkets.com/research/5rhbrc/global
